JP2013542264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542264A5 JP2013542264A5 JP2013538939A JP2013538939A JP2013542264A5 JP 2013542264 A5 JP2013542264 A5 JP 2013542264A5 JP 2013538939 A JP2013538939 A JP 2013538939A JP 2013538939 A JP2013538939 A JP 2013538939A JP 2013542264 A5 JP2013542264 A5 JP 2013542264A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- inhibition
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 13
- 230000005764 inhibitory process Effects 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 6
- 229960000397 bevacizumab Drugs 0.000 claims 6
- 229960004562 carboplatin Drugs 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 230000000970 DNA cross-linking effect Effects 0.000 claims 2
- 230000002112 DNA intercalation Effects 0.000 claims 2
- 230000006820 DNA synthesis Effects 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 102000029749 Microtubule Human genes 0.000 claims 2
- 108091022875 Microtubule Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 101710183280 Topoisomerase Proteins 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- -1 bevacizumab Chemical compound 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 210000004688 microtubule Anatomy 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 0 CC(C)=CCCNc(cc1)ccc1C(NC(CCC(NCC(NC(CCCNC(N)=N)C(NCC(N[C@@](CC(O)=O)C(NC(*)CSSCCOC(NNC([C@]1(C(*)C2C=CCN(CC3)C2C32c(cc(C)c(OC)c3)c3N(C)C12)O)=O)=O)=O)=O)=O)=O)=O)C=O)=O Chemical compound CC(C)=CCCNc(cc1)ccc1C(NC(CCC(NCC(NC(CCCNC(N)=N)C(NCC(N[C@@](CC(O)=O)C(NC(*)CSSCCOC(NNC([C@]1(C(*)C2C=CCN(CC3)C2C32c(cc(C)c(OC)c3)c3N(C)C12)O)=O)=O)=O)=O)=O)=O)=O)C=O)=O 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VORHXBNOSKWXDL-UHFFFAOYSA-N NC(C(N)=O)=C(N)N Chemical compound NC(C(N)=O)=C(N)N VORHXBNOSKWXDL-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41327510P | 2010-11-12 | 2010-11-12 | |
| US61/413,275 | 2010-11-12 | ||
| PCT/US2011/060407 WO2012065085A1 (en) | 2010-11-12 | 2011-11-11 | Methods of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013542264A JP2013542264A (ja) | 2013-11-21 |
| JP2013542264A5 true JP2013542264A5 (enExample) | 2014-12-25 |
Family
ID=46048353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538939A Pending JP2013542264A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
| JP2013538937A Pending JP2013542263A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538937A Pending JP2013542263A (ja) | 2010-11-12 | 2011-11-11 | 癌を処置する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8883737B2 (enExample) |
| EP (2) | EP2638397A4 (enExample) |
| JP (2) | JP2013542264A (enExample) |
| KR (2) | KR20130140032A (enExample) |
| CN (2) | CN103403552B (enExample) |
| AU (2) | AU2011325982C1 (enExample) |
| BR (2) | BR112013011590A2 (enExample) |
| CA (2) | CA2817219A1 (enExample) |
| CL (2) | CL2013001324A1 (enExample) |
| EA (2) | EA026168B1 (enExample) |
| IL (2) | IL226246A0 (enExample) |
| MX (2) | MX2013005196A (enExample) |
| SG (2) | SG190245A1 (enExample) |
| WO (2) | WO2012065079A1 (enExample) |
| ZA (2) | ZA201304225B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1789391B1 (en) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| KR20130140032A (ko) | 2010-11-12 | 2013-12-23 | 엔도사이트, 인코포레이티드 | 암을 치료하는 방법들 |
| KR20140022879A (ko) * | 2011-04-12 | 2014-02-25 | 엔도사이트, 인코포레이티드 | 고체 약학 조성물 |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| US11162937B2 (en) | 2013-11-19 | 2021-11-02 | Purdue Research Foundation | Patient selection method for inflammation |
| SI3134123T1 (sl) | 2014-02-21 | 2021-08-31 | Nektar Therapeutics (India) Pvt. Ltd. | IL-2Rbeta-selektivni agonisti v kombinaciji s protitelesom proti- CTLA-4 ali protitelesom proti-PD-1 |
| CN103816548A (zh) * | 2014-03-11 | 2014-05-28 | 北京林业大学 | 靶向亲水性聚合物-雷公藤甲素结合物 |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| EP3131587A4 (en) * | 2014-04-14 | 2017-11-01 | Endocyte, Inc. | Drug delivery conjugates for treating resistant cancer and for use in combination therapy |
| EP3826613B1 (en) * | 2018-08-31 | 2024-11-20 | Sun Pharmaceutical Industries Limited | Parenteral dosage form of carboplatin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| US7910594B2 (en) * | 2002-05-15 | 2011-03-22 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| AR042942A1 (es) * | 2003-01-27 | 2005-07-06 | Endocyte Inc | Conjugados de administracion de drogas de union de receptores de vitaminas |
| CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
| EP1864133B1 (en) * | 2005-03-30 | 2010-03-10 | Purdue Research Foundation | Method for breastcancer prognosis using cellular folate vitamin receptor quantification |
| WO2007022493A2 (en) * | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Ligand conjugates of vinca alkaloids, analogs, and derivatives |
| US20070065449A1 (en) * | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| JP5675619B2 (ja) * | 2008-09-17 | 2015-02-25 | エンドサイト, インク.Endocyte, Inc. | 葉酸拮抗薬の葉酸受容体結合性コンジュゲート |
| WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
| CN104857534A (zh) * | 2009-07-31 | 2015-08-26 | 恩多塞特公司 | 叶酸盐靶向的诊断和治疗 |
| KR20130140032A (ko) | 2010-11-12 | 2013-12-23 | 엔도사이트, 인코포레이티드 | 암을 치료하는 방법들 |
-
2011
- 2011-11-11 KR KR1020137013270A patent/KR20130140032A/ko not_active Ceased
- 2011-11-11 BR BR112013011590A patent/BR112013011590A2/pt not_active IP Right Cessation
- 2011-11-11 CA CA2817219A patent/CA2817219A1/en not_active Abandoned
- 2011-11-11 MX MX2013005196A patent/MX2013005196A/es unknown
- 2011-11-11 EP EP11840607.3A patent/EP2638397A4/en not_active Withdrawn
- 2011-11-11 JP JP2013538939A patent/JP2013542264A/ja active Pending
- 2011-11-11 CA CA2817223A patent/CA2817223A1/en not_active Abandoned
- 2011-11-11 JP JP2013538937A patent/JP2013542263A/ja active Pending
- 2011-11-11 CN CN201180061415.4A patent/CN103403552B/zh not_active Expired - Fee Related
- 2011-11-11 EA EA201390695A patent/EA026168B1/ru not_active IP Right Cessation
- 2011-11-11 CN CN2011800634321A patent/CN103282777A/zh active Pending
- 2011-11-11 BR BR112013011659A patent/BR112013011659A2/pt not_active IP Right Cessation
- 2011-11-11 AU AU2011325982A patent/AU2011325982C1/en not_active Ceased
- 2011-11-11 AU AU2011325989A patent/AU2011325989C1/en not_active Ceased
- 2011-11-11 KR KR1020137013272A patent/KR20130140033A/ko not_active Ceased
- 2011-11-11 WO PCT/US2011/060395 patent/WO2012065079A1/en not_active Ceased
- 2011-11-11 US US13/884,842 patent/US8883737B2/en not_active Expired - Fee Related
- 2011-11-11 US US13/294,624 patent/US8987281B2/en not_active Expired - Fee Related
- 2011-11-11 SG SG2013036306A patent/SG190245A1/en unknown
- 2011-11-11 MX MX2013005194A patent/MX2013005194A/es unknown
- 2011-11-11 EA EA201390694A patent/EA025069B1/ru not_active IP Right Cessation
- 2011-11-11 SG SG2013036280A patent/SG190244A1/en unknown
- 2011-11-11 EP EP11839397.4A patent/EP2638395A4/en not_active Withdrawn
- 2011-11-11 WO PCT/US2011/060407 patent/WO2012065085A1/en not_active Ceased
-
2013
- 2013-03-13 US US13/800,254 patent/US20140066383A1/en not_active Abandoned
- 2013-05-09 IL IL226246A patent/IL226246A0/en unknown
- 2013-05-09 IL IL226247A patent/IL226247A0/en unknown
- 2013-05-13 CL CL2013001324A patent/CL2013001324A1/es unknown
- 2013-05-13 CL CL2013001322A patent/CL2013001322A1/es unknown
- 2013-06-10 ZA ZA2013/04225A patent/ZA201304225B/en unknown
- 2013-06-10 ZA ZA2013/04226A patent/ZA201304226B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542264A5 (enExample) | ||
| JP2013542263A5 (enExample) | ||
| JP2014525449A5 (enExample) | ||
| CN103945902B (zh) | 地西他滨衍生物制剂 | |
| WO2007082978A1 (es) | Una formulación farmacéutica de taxano, una composición sólida de taxano, un procedimiento para la preparación de dicha composición sólida de taxano, una composición solubilizante de dicha composición sólida de taxano, y un conjunto de elementos (kit) par | |
| RU2723590C2 (ru) | Лиофилизированные фармацевтические композиции | |
| JP2019526596A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| RU2016141569A (ru) | Комбинации | |
| ES2414472T3 (es) | Composición farmacéutica de liberación sostenida de acetato de octreotide | |
| KR20170023088A (ko) | 정제된 치료용 나노입자 및 이의 제조방법 | |
| JP2019515908A5 (enExample) | ||
| JP2015535243A5 (enExample) | ||
| JP2011507838A5 (enExample) | ||
| CN111888329A (zh) | 注射剂 | |
| JP2016521731A (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
| CN107405404A (zh) | 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途 | |
| EP3197430A1 (en) | Long acting pharmaceutical compositions | |
| JP2013541587A (ja) | Ｎｅｄｄ８活性化酵素阻害剤の投与 | |
| JP2021505669A5 (enExample) | ||
| JP2017505313A5 (enExample) | ||
| WO2014165829A3 (en) | Nanoparticle formulations | |
| Li et al. | Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer | |
| EP1965804A2 (en) | Lyophilized compositions of a triazolopyrimidine compound | |
| RU2018114922A (ru) | Лечение очаговой алопеции |